Epidemiology of contralateral breast cancer.

Two to 11% of women diagnosed with breast cancer will develop contralateral breast cancer in their lifetime. Women with a first primary are at a 2-6-fold increased risk of developing contralateral breast cancer compared with the risk in the general population of women developing a first primary cancer. The incidence rate of contralateral breast cancer varies from four to eight per 1000 person-years. To assess the risk factors associated with the development of contralateral breast cancer among women with a first primary breast cancer, the epidemiological literature concerning these factors was reviewed and summarized. Studies have shown that a family history of breast cancer, an early age at initial diagnosis, and a lobular histology of the first primary breast cancer increase the risk of developing contralateral breast cancer. Although chemotherapy and tamoxifen therapy may reduce this risk, there are inconsistent results regarding the effects of radiotherapy and the effects of reproductive, environmental and other factors. Additional analytical studies addressing all potential risk factors associated with the development of contralateral breast cancer are necessary in view of the increasing incidence and survival of women with a first primary.

[1]  N. Risch,et al.  Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. , 1992, American journal of epidemiology.

[2]  M. Yoshida,et al.  Risk factors of multiple primary cancers in breast cancer patients. , 1986, Japanese journal of cancer research : Gann.

[3]  H. Storm,et al.  Risk of contralateral breast cancer in Denmark 1943-80. , 1986, British Journal of Cancer.

[4]  B. Asselain,et al.  Contralateral breast cancer: annual incidence and risk parameters. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[6]  B. Webber,et al.  Risk of subsequent contralateral breast carcinoma in a population of patients with in‐situ breast carcinoma , 1981, Cancer.

[7]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[8]  Brinton La,et al.  Second cancer following cancer of the breast in Connecticut, 1935-82. , 1985 .

[9]  B. Hankey,et al.  A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. , 1983, Journal of the National Cancer Institute.

[10]  Thompson Wd,et al.  Exposure to chemotherapeutic agents and the risk of a second breast cancer: preliminary findings. , 1988 .

[11]  S. Paik,et al.  Pathologic findings from the national surgical adjuvant breast project (protocol 6) I. Intraductal carcinoma (DCIS) , 1986, Cancer.

[12]  H. Adami,et al.  Bilateral carcinoma of the breast. Epidemiology and histopathology. , 1981, Acta radiologica. Oncology.

[13]  H. Storm,et al.  Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. , 1991, Journal of the National Cancer Institute.

[14]  A. Jacobsen,et al.  Adjuvant radiotherapy and risk of contralateral breast cancer. , 1992, Journal of the National Cancer Institute.

[15]  N. Risch,et al.  The genetic epidemiology of second primary breast cancer. , 1992, American journal of epidemiology.

[16]  T. Hiyama,et al.  Second primary cancers following female breast cancer in Osaka, Japan--a population-based cohort study. , 1987, Japanese journal of clinical oncology.

[17]  G F ROBBINS,et al.  Bilateral primary breast cancers. A prospective clinicopathological study , 1964 .

[18]  Thompson Wd,et al.  RISK OF CONTRALATERAL BREAST CANCER: ASSOCIATIONS WITH FACTORS RELATED TO INITIAL BREAST CANCER , 1988 .

[19]  N. Weiss,et al.  Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. , 1995, Journal of the National Cancer Institute.

[20]  F. Ames,et al.  Bilateral carcinoma of the breast: frequency and mortality. , 1978, Canadian journal of surgery. Journal canadien de chirurgie.

[21]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[22]  Cancer in the contralateral breast after radiotherapy for breast cancer. , 1992, The New England journal of medicine.

[23]  H. Adami,et al.  Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population‐based case‐control study , 1985, Cancer.

[24]  Thompson Wd.  Methodologic perspectives on the study of multiple primary cancers , 1986 .

[25]  W. Thompson,et al.  Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut Tumor Registry. , 1987, Journal of chronic diseases.

[26]  H. Brenner,et al.  Second primary neoplasms following breast cancer in Saarland, Germany, 1968-1987. , 1993, European journal of cancer.

[27]  E. Cook,et al.  Contralateral breast cancer: clinical characteristics and impact on prognosis. , 1993, Journal of Clinical Oncology.

[28]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .

[29]  N. Weiss,et al.  Risk of contralateral breast cancer among women with carcinoma in situ of the breast. , 1997, Annals of surgery.

[30]  B. Fisher,et al.  Pathologic findings from the national surgical adjuvant breast project (protocol no. 4): XI. Bilateral breast cancer , 1984, Cancer.

[31]  P. Horn-Ross,et al.  Multiple primary cancers involving the breast. , 1993, Epidemiologic reviews.

[32]  R. Arriagada,et al.  Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies , 1991, The Lancet.

[33]  S. Groshen,et al.  Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. , 1989, Surgery.

[34]  S. Duffy,et al.  Infiltrating lobular carcinoma of the breast: An evaluation of the incidence and consequence of bilateral disease , 1983, The British journal of surgery.

[35]  L. Prosnitz,et al.  Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer , 1990, Cancer.

[36]  A. S. Neto,et al.  Bilateral breast cancer at the Johns Hopkins hospital A discussion of the dilemma of contralateral breast cancer , 1971, Cancer.

[37]  M. Badzioch,et al.  Bilaterality in familial breast cancer patients , 1985, Cancer.

[38]  P. Prior,et al.  Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiological analysis. , 1978, British Journal of Cancer.

[39]  J. Cuzick,et al.  Bilateral primary breast cancer: A prospective study of disease incidence , 1984, The British journal of surgery.

[40]  L. Skoog,et al.  Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. , 1991, Journal of the National Cancer Institute.

[41]  C. Bodian,et al.  Breast Carcinoma: Risk and Detection , 1981 .

[42]  J. Kurtz,et al.  Contralateral breast cancer and other second malignancies in patients treated by breast-conserving therapy with radiation. , 1988, International journal of radiation oncology, biology, physics.

[43]  J. Enstrom,et al.  Contralateral Breast Cancers following Treatment for Initial Breast Cancers in Women , 1989, American journal of clinical oncology.

[44]  A. Coldman,et al.  Radiation dose and second breast cancer. , 1985, British Journal of Cancer.

[45]  Nils Wilking,et al.  ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS , 1989, The Lancet.

[46]  A. Lees,et al.  Bilateral breast cancer in northern Alberta: risk factors and survival patterns. , 1984, Canadian Medical Association journal.

[47]  H. Stewart.  The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. , 1992, Journal of the National Cancer Institute. Monographs.

[48]  D. Schottenfeld,et al.  Incidence of Multiple Primary Cancers. IV. Cancers of the Female Breast and Genital Organs , 1971 .

[49]  J. McCredie,et al.  Consecutive primary carcinomas of the breast , 1975, Cancer.

[50]  H. Johansson,et al.  Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. , 1995, Journal of the National Cancer Institute.

[51]  G. Sakamoto,et al.  Bilateral breast cancer and familial aggregations. , 1978, Preventive medicine.

[52]  W. Thompson,et al.  Risk of contralateral breast cancer associations with histologic, clinical, and therapeutic factors , 1988, Cancer.